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1. Introduction  
 
1.1. Role of conjunctival normal flora 
 
The normal bacterial flora of the lids and conjunctiva have been thoroughly studied since 
the inception of bacteriology [11,64]. The conjunctival surface is colonized by a population of 
bacteria and fungi that, although fairly constant in number, undergo a continual cyclic repetitive 
change in species [11,64]. Before birth, the conjunctiva and eyelids are sterile if the amniotic sac is 
not ruptured. Bacterial flora are acquired during passage through the birth canal. After birth, 
healthy persons of all ages show approximately the same distribution of bacterial species. As is 
true of age, other variables such as right versus left eye, sex, or seasons of the year do not affect the 
bacterial population [11,64]. The source of bacteria populating the eye is the skin. This has been 
determined by culturing conjunctiva, lids, and face, nose and hand skin [7]. Previous studies from 
Allansmith et al.[3] suggested that the bacterial flora of the two eyes is similar. A specific bacteria 
was from two to ten times more likely to be cultured from one eye if present in the other eye [32]. 
Coagulase-negative Staphylococcus (CNS) (37%) are a major component of the normal 
bacterial flora of human eyelids and conjunctiva [4,67]. Less frequent bacteria are Staphylococcus 
aureus (17%) and Corynebacterum sp (1%) [4]. Studies of anaerobic bacteria in the eye have been 
performed less frequently than those involving cultures of aerobes. Propionibacterium acnes is by 
far the most common and should be considered as indigenous micro-flora [53]. Fungi are normal 
inhabitants of the eye, probably falling out of dust from the air onto the surfaces of the eye [53]. 
While a great number of species can be cultured from the eyelid margin and ocular surface, it is 
known by special studies that in 45% to 52% of subjects, most of these species are not considered 
pathogens [23,53]. However, following trauma or inmunosupression, normally benign fungi, even 
those never known previously to cause human disease, are capable of inducing corneal infection 
with subsequent intraocular extension and blindness [7,67]. 
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1.1.1. Natural control mechanisms of indigenous flora of the eye  
Probably the most important mechanism for control of the bacterial flora of the eye are the 
dust-filtering eyelashes, the eyelids, and the lacrimal apparatus [56]. The human blinks 10 to 15 
times a minute. Each time the eyelids blink, they mechanically sweep tear film fluid, mucus, 
and suspended bacteria medially toward the lacrimal puncta [56]. The mechanical vacuuming 
effect of the eyelid muscles on the tear sac sucks the bacterial flora down the lacrimal duct to 
the nose [56]. Increased production of tears might aid in removal of microorganisms [7]. 
Competitive interactions exist among those bacterial species found on the eye. In particular, 
staphylococci and diphtheroids seem to have antibiotic properties directed against each other 
[7]. There is some evidence that these two genera tend to inhibit each other and that an 
overgrowth of one leads to suppression of the other [40]. Further, different strains or species of 
staphylococci may have the ability to interfere with the growth of each other. This may be a 
reflection of nature’s ecological balance among species so that one bacterium is able to live in 
relative symbiosis with another without depleting nutritional resources [7,40]. The way how the 
bacteria, sometimes considered normal flora, become pathogenic is not clear, but one step is 
adherence of the microorganism to the host cell [7]. Adherence of bacteria by means of pili to 
depressions in epithelial cells is another mechanism by which disease pathogenesis might occur. 
Adherence occurs more to damaged epithelial cells than to non-damaged epithelium or denuded 
stroma [40].  
The tear fluid is a potent inhibitor of bacterial growth on the eye. Lysozyme is a protein tear 
component that has a non-specific antibacterial effect that lyses bacterial cell walls [46]. 
Although this substance is found in higher concentration in tears than other body fluids, it is 
probably a minor component of the ocular protection. Also lysozyme may possibly have an 
adverse effect in that S. aureus that are resistant to lysozyme may be selectively increased in β-
lactamase production and hence have increased antibiotic resistance [46]. Another protein 
component of the tears, lactoferrin may be of some importance in inhibiting the bacterial flora 
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of the eye by its iron-binding capacity [46,10]. An important tear component in resisting 
bacterial infection is immunoglobulin A [48,10]. As in other glandular tissues that secrete fluids 
or mucus on the internal or external surface of the body, the lacrimal gland has the ability to 
couple a secretory “T piece” to the immunoglobulin molecules circulating in the blood [48]. 
This secretory immunoglobulin A is a highly effective antimicrobial agent against some 
organisms and occurs in the normal tear fluid in a concentration of 50 mg to 60 mg/dl [48,10]. 
Since the external surface of the eye is joined from cell to cell with no gaps in between, the 
normal eye has an effective mechanical barrier composed of its normal cells. When this physical 
barrier is broken mechanically, infection and invasion by foreign agents are facilitated [27]. 
 
1.2. Chronic Blepharitis  
 Chronic blepharoconjunctivitis (CBC) is one of the most common ocular diseases of the 
eyelids and conjunctiva encountered in clinical practice, but surprisingly, it is not often recognized 
and can be associated with symptoms such as a burning sensation, irritation, tearing, photophobia, 
blurred vision, and red eyes [10,65]. Clinical examination typically reveals the presence of scurf, 
telangiectatic vascular changes of the eyelid margin, inspissated meibomian glands, conjunctival 
hyperemia, and rarely, punctuate keratopathy, cornea vascularization and ulceration [12,28,45]. 
Epidemiologic data indicates that blepharitis and conjunctivitis account for approximately 71% of 
cases presenting to general medical clinics with ocular inflammation [12,65]. The prevalence is 
higher in elderly patients. Attempts to classify this disorder are difficult because of the complex 
mechanisms underlying its pathogenesis. Clinical and laboratory investigations have clearly 
established bacteria and meibomian gland abnormalities as major etiologic determinants as well as 
changes in tear film dynamics and underlying dermatologic diseases [65]. The conjunctival flora in 
patients with CBC has been reported to be comprised of elevated amounts of bacteria compared to 
normal individuals. Bacterial lipase changes the secretion of the meibomian glands. Thus, 
cholesterol concentration increases through the cholesterol esterase enzymatic division that favors 
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bacterial growth and proliferation. This suggests that bacterial populations and their corresponding 
lipase/esterase activity may play an important role in promoting the development of blepharitis 
[17,24]. 
1.2.1. Clinical features and Classification 
The eyelid is a complex structure anatomically and functionally. Anatomically, the eyelid 
margin is comprised of diverse elements, including skin, lashes, their associated pilosebaceous 
apparatus, the cartilage-like tarsus in which the meibomian glands are found and the conjunctival 
mucous membrane [56]. Functionally, the eyelid provides mechanical protection of the ocular 
surface, maintains a continuous tear film over the epithelial surface, and supplies essential 
components of the tear film, especially the lipid secretory product of the meibomian glands that 
forms the outer layer of the tear film [44,45,54]. 
Blepharitis is often low grade, chronic and asymptomatic. Common symptoms are mild 
ocular irritation with a frequent foreign body sensation, redness, crusting, itching and burning [34]. 
There is often a history of styes or chalazia of the eyelid [5]. The signs associated with blepharitis 
may be confined to the eyelid, such as erythema of the lid margin, collarettes (scales surrounding 
the base of the eyelashes), madarosis (loss of eyelashes), trichiasis (misdirection of eyelashes), 
notching of the lid margin, and overflow or plugging of the meibomian glands [5]. Frequently, there 
is an associated conjunctivitis with erythema and edema, but this is usually without discharge. 
Papillary hypertrophy of the tarsal conjunctiva is often noted. Superficial punctuate erosions of the 
inferior cornea epithelium, frequently concentrated at the inferior limbus, are common and are 
associated with more severe symptoms [5]. Because of the intimate relationship between the lids 
and ocular surface, chronic blepharitis may cause secondary changes in the conjunctiva and cornea 
[34,48,65,]. 
Blepharitis has been difficult to categorize because it consist of a varied collection of 
clinical entities, which manifest differently but sometimes present with overlapping signs and 
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symptoms. Over the years, several classification schemes for categorizing the different types of 
blepharitis have been proposed [45]. 
 
Thygeson [70] 
 
 
 
 
1946 
 
 
 
 
Divided blepharitis into 3 
etiologic types based on 
distinct clinical characteristics 
 
 
a. Staphylococcal  
b. Seborrheic 
c. Diplobacillary 
blepharitis. 
 
McCulley et 
al.[45] 
 
 
 
 
 
 
 
 
 
 
1982 
 
 
 
 
 
 
 
 
 
 
More elaborate classification 
scheme subdivided into 6 
groups, based on the 
characteristic of the eyelid, 
lashes, hair follicles, 
meibomian orifices, debris on 
the lid margin and corneal 
changes.  
 
a. Staphylococcal 
blepharitis  
b. Seborrheic alone 
c. Seborrheic with 
staphylococcal  
d. Seborrheic with 
meibomian seborrhoea 
e. Seborrheic with 
secondary meibomitis  
f. Primary meibomitis  
Huber-Spitzy et 
al.[28] 
 
 
 
1991 
 
 
 
 
Based on clinical features  
 
 
 
 
a. Blepharitis sicca 
b. Blepharitis seborrheica 
c. Blepharitis Ulcerosa 
 
Mathers et al.[42]  1991 Based on the degree of 
meibomian gland loss, tear 
film osmolarity, and the 
results of Schirmer testing. 
 
a. Seborrheic meibomian 
gland dysfunction  
b. Obstructive meibomian 
gland dysfunction  
c. Obstructive with sicca  
d. Pure sicca 
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Wilhelmus [73] 1992 Based on an anatomic 
delineation of the lid margin 
according to the gray line. The 
gray line (muscle of Riolan) 
divides the lid into an anterior 
lamella (skin and muscle) 
(eyelashes follicles and 
associated glands of Zeiss are 
part) and posterior lamella 
(tarsus and conjunctiva) (the 
meibomian glands are part of 
this) 
a. Anterior lid margin 
blepharitis 
b. Posterior lid margin 
blepharitis  
 
According to all previously mentioned classification schemes, blepharitis can be classified 
anatomically in 2 principal groups. 
a. Anterior lid margin 
• Staphylococcal 
• Seborrheic 
• Mixed 
b. Posterior lid margin  
• Meibomian Seborrhoea 
• Meibomianitis  
 
Anterior lid margin: Staphylococcal blepharitis  
 Staphylococcal blepharitis is caused by a chronic inflammation of the lash basis with tiny 
intrafollicular abscesses. Dermal and epidermal ulceration and tissue destruction are the 
consequences. Staphylococcal blepharitis is frequently found in patients with atopic eczema and 
demonstrates a gender predilection, with 80 % of patients being female. In addition it tends to occur 
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in younger patients [45]. The mean age of patients with staphylococcal blepharitis is 42 years, 
whereas the mean age of patients with other forms of blepharitis is 51 years [35,45]. 
 Clinical Features: The characteristic symptoms associated with staphylococcal blepharitis 
include burning, itching, photophobia, and an irritating sandy, gritty sensation, which is frequently 
worse upon awakening [27]. The principal clinical signs manifest primarily on the anterior lid 
margin, palpebral conjunctiva and the cornea. Distinctive lid margin features are hard, fibrinous 
crusting scales on the anterior lid margin that surround individual cilia as collarette. Dilated blood 
vessels (rosettes) produce hyperemia of the lid margins [27]. Chronic inflammation leads to 
irregularity or notching and thickening of the lid margin (tylosis) thinning or loss of lashes 
(madarosis), white lashes (poliosis), and misdirected lashes (trichiasis) [34]. Kanski [28] previously 
showed that acute staphylococcal infections may produce external hordeola from acute purulent 
occlusion of the glands of Zeiss or internal hordeola from acute inflammation of the meibomian 
glands. Secondary changes through hyper sensitivity to staphylococcal toxins include the following 
features:  
• Low papillary conjunctivitis,  
• Punctate epithelial keratitis, which commonly affects the inferior one-third of the cornea 
• Marginal keratitis (catarral ulcers) 
• Phlyctenular keratitits and a peripheral wedge-shaped pannus may develop in the area of 
previous ulceration, 
•  Associated instability of the tear film will be observed in 50% of the cases 
 
Anterior lid margin: seborrheic blepharitis 
 The seborrheic blepharitis is a disease of the Zeiss- Moll glands and is frequently associated 
with seborrheic dermatitis which may involve the scalp, eyebrows, nasolabial folds, retroauricular 
areas, and sternum. The two principal forms of seborrheic blepharitis are: the greasy type, with 
which the scales eruptions are greasy, and the dry type (Pityriasis capitis or dandruff) [34]. It has 
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been postulated that excessive amounts of neutral lipids in patients with seborrhoea are broken 
down by Corynebacterium acnes into bacterial lipase and irritating fatty acids. The seborrheic 
blepharitis can appear isolated or with staphylococci or interconnected with posterior blepharitis. 
The symptoms of purely seborrheic blepharitis are similar to staphylococcal blepharitis, but less 
heavily, with seldom exacerbation. Approximately 30 % of the patients have associated tear film 
instability. Clinical Features: hyperaemic and greasy anterior lid margins with sticking together of 
lashes. The scales are soft and located anywhere on the lid margin and lashes [35]. 
 
Posterior lid margin: blepharitis 
Posterior blepharitis is manifested as a meibomian dysfunction and can be associated with 
anterior blepharitis or it may occur in isolation. Complications are chalazion formations, which may 
be recurrent, as well as tear film instability in about 30% of patients. This is probably the result of 
an imbalance between the aqueous and lipid components of the tear film, allowing increased 
evaporation and dryness. Others complications are papillary conjunctivitis and inferior corneal 
epithelial erosions. The two main types are meibomian seborrhoea and meibomianitis [35]. 
Meibomian seborrhoea is characterized by excessive meibomian gland secretions. It is easily 
missed because symptoms may be severe but clinical signs of blepharitis are mild. The meibomian 
gland orifices are often capped by small oil globules. Pressure on the tarsus results in expression of 
copious amounts of meibomian oil. The tear film is oily and foamy and in severe cases froth 
accumulates on the lid margins or inner canthi (meibomian foam) [35]. 
Meibomianitis: this is characterized by inflammation and obstruction of the meibomian 
glands [46]. The posterior lid margin shows hyperaemia, telangiectasia and obstruction of 
meibomian gland orifices. Long-standing cases are characterized by cystic dilatation of meibomian 
ducts, with thickening and notching of the lid margin. Expressed meibomian gland secretions in 
long-standing cases may be turbid or inspissated, appearing as toothpaste-like plaque. In every 
severe cases no secretions can be expressed [35]. 
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1.2.2. Pathogenesis 
Skin Diseases 
Frequently, a skin illness underlies the chronic blepharitis. One third of these patients suffer 
from seborrheic dermatitis, which is characterized through the hyper keratinisation of the skin, 
especially in sebaceous glandular rich areas. An overproduction of sebum, however, should not be 
present. Seborrheic dermatitis was found in 100% of the patients with seborrheic blepharitis and 
secondary meibomitis and in 82% of the patients with seborrheic blepharitis [45]. 
In more than one third of the patients with chronic blepharitis, rosacea is present. Practically, 
all rosacea patients suffer from chronic blepharitis with meibom gland involvement and 20% of 
blepharitis precedes a skin manifestation. Chalazions develop often in patients with rosacea. Ten 
percent of patients with chronic blepharitis suffer from atopic dermatitis. An ectodermal dysplasia, 
in which the meibom glands are missing, can also lead to chronic blepharitis [27]. 
An abnormal keratinisation of the meibom gland excretory duct, which occurs frequently in 
the above mentioned skin diseases, seems to be important for the pathogenesis of chronic 
blepharitis. This is especially true for the form of blepharitis with blockage of the meibom gland 
excretory duct without substantial bacterial participation. Histologically, an increase in 
keratinocytes is present in the openings and excretory ducts of the meibom glands [5]. 
 
Bacterial Infections 
Bacteria have been implicated to play a significant role in the pathogenesis of chronic 
blepharitis [4,24,52]. Studies showed, that this is the case in 2 subtypes, namely staphylococcal 
blepharitis and combined seborrheic/staphylococcal blepharitis. In this case, coagulase-negative 
staphylococci, Propionibacterium acnes or Pityrosporum ovale were detected in eyelid margin 
cultures that had a bacterial lipase which altered meibomian gland secretion. Staphylococcus aureus 
and Propionibacterium acnes build wax esterase and triglyceride lipase, in addition Staphylococcus 
aureus builds a cholesterol esterase [17,45]. The bacteria mentioned are also found in normal eyelid 
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margins, however they are possibly present in a greater number in chronic blepharitis and special 
strains could be responsible for the inflammatory eyelid illness [19].  
Bacterial lipases change the secretion of the meibomian glands, whose cholesterol content 
increases through enzymatic scission of cholesteryl ester, which in turn benefits bacterial growth 
and propagation, especially from Staphylococcus aureus. The bacterial colonization of the eye lid 
margins and their lipase/ester activity support the development of chronic blepharitis. The presence 
of cholesteryl ester (and its decomposition product cholesterol) is clearly necessary for the 
development of a dysfunction of the meibom glands [61]. 
Bacterial lipoposaccharide trigger the formation of cytokine- like tumor necrosis factor-α 
(TNF- α), through phagocyte white blood cells or through normal cells such as keratinocytes. 
Cytokines lead to a rise in reactive oxygen species (ROS), which favors chronic blepharitis and 
keratoconjunctivitis through a subsequent accumulation of nitrogen oxide (NO) and 4-hydroxy 
nonenal (HNE) [36]. 
Chronic blepharitis is possibly a consequence of a cell mediated hypersensitivity reaction, an 
exotoxin, or from changes of the meibom-gland-fat through the location specific bacterial flora and 
their respective lipase, and rarely from an immediate infection [5]. 
 
Others lid infections 
Parasitic: Demodex folliculorum. Is a microscopic, obligate, hair follicle mite that is the 
most common permanent ectoparasite of humans [57]. Demodex folliculorum as a further 
pathogenic factor of chronic blepharitis remains in discussion. Studies have demonstrated that the 
incidence of the parasite was very high in patients with chronic blepharitis compared with normal 
subjects (52%) [15,71]. 
Treatment of demodicosis of the eyelids as a general rule lasts a few months. The use of 
yellow mercurial ointment, sulphur ointment, camphorated oil, crotamiton, choline esterase 
inhibitors, sulfacetamide, steroids, antibiotics, as well as antimycotic drugs offers some 
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improvement. A good response has been observed after oral application of ivermectin along with 
topical application of cream permethrin. However, the best results were obtained after 2% 
metronidazole gel or ointment treatment [14]. 
 
Fungal: Candida infections of the eyelid are uncommon and are usually associated with 
candidal infections elsewhere. Normally, the infection occurs in immunosuppressed patients or 
those taking glucocorticoids. Small ulcers, vesicles, or pustules can develop at the bases of the 
eyelashes. The infection responds to topical nystatin dermatologic cream or topical amphotericin B 
[30]. A study by Huber et al.[29] suggested when Candida species happen to coincide with severe 
inflammation in atopic patients a blepharitis of the ulcerative type will develop or deteriorate 
thereby implying that these microorganisms may play an important role in the development or 
deterioration of this severe chronic inflammation.  
Ringworm (tinea faciale) is a dermatophyte that can affect the eyelid primarily or spread to 
the eyelid from other parts of the face. The early lesions begin as flattened, reddish papules that 
spread peripherally while the central area heals. The fully developed lesion has a ring-like 
appearance, with a reddish, scaly, sharply defined border and a central pinkish scaly area. The 
lesions usually respond to topical salicylic acid (1%) and precipitated sulphur (3%) in hydrophilic 
ointment twice daily for 3 to 5 days [30].  
 
Viral: Molluscum contagiosum infections are characterized by elevated, round, waxy, 
pearly-white, noninflammatory lesions with umbilicated centers. The lesions can be single or 
multiple and, when located on or near the lid margin, usually cause a chronic follicular 
conjunctivitis, superior pannus, and superior epithelial keratitis simulating trachoma. Removal or 
expression of the nodule, allowing permeation of blood into its substance, is curative [30]. 
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  Herpes simplex virus can infect the lid either as primary or recurrent infection. The infection 
is characterized by vesicles on an erythematous base that usually progress to ulcers. Cleansing of 
the eyelid with cool saline solution is helpful [30].   
Herpes zoster virus involvement of the ophthalmic branch of the fifth cranial nerve often 
affects the upper eyelid, whereas involvement of the maxillary branch often affects the lower eyelid. 
The lesions have a dermatomal distribution and are vesicular, and later ulcerative. Treatment with 
systemic acyclovir is indicated [30].  
 
Other changes of the meibom-gland secretion  
Apart from the above mentioned bacterial changes in the composition of cholesteryl ester, 
other pathological changes of the secretion of the meibom glands have been described in chronic 
blepharitis:  
Polar fats with a coat thickness of 1-3 molecules act as surfactants between the aqueous 
phase and the non-polar fat phase of the lachrymal coat. The polar lipids and the fatty acids that 
derive from them are highly unsaturated in meibomitis and they are different not only from the 
control group without blepharitis, but also from those with other blepharitis subtypes [60].  
Meibom gland secretion from patients with chronic blepharitis contains twice the amount of 
secreted phospholipases A2 (sPLA2) in comparison to healthy patients. This is significant because 
the sPLA2-activity induces the release of the pro-inflammatory arachidonic acid, an unsaturated 
fatty acid which acts as a precursor of prostaglandin E2 (PgE2) and leukotriene B4. PgE2, 
leukotriene B4 and arachidonic acid activate the inflammation-promoting TNF-α. The 
inflammation-promoting fat aldehyde HNE is produced in the presence of ROS from unsaturated 
fatty acids like linoleic acid. The loss of polar lipids, including the “transition”-triglycerides can 
destabilize the tear film by the non-polar lipid layer only restraining the water evaporation 
insufficiently or the influence on the boundary layer and its triglycerides between the polar and non-
polar layer [47]. 
 17
Other studies discovered that simple unsaturated fatty acids from wax/sterol ester are 
elevated in patients with chronic blepharitis, in comparison to healthy patients. In contrast to this, a 
decrease of simply unsaturated non-polar oil acids in chronic blepharitis, especially in meibomitis, 
was found with an increase in the melting point and secretal hardening along with normal surface 
temperature of the eye with a following obstruction of the meibom gland excretory duct. Under 
normal conditions, the melting point of the secretion from the meibom glands lies between 10°C to 
32°C [18,47]. 
The accumulation of irritating substances like fatty acids, the destabilisation of the fat layer 
through an increase of polar substances and a suitable environment for bacteria promote chronic 
blepharitis [19]. 
Impression-cytology of the conjunctiva in patients with chronic blepharitis showed defects 
in the epithelial cells with tears in the intercellular connections, lost of becher´s cell, and 
subsequently, a defect in the mucin secretion. These changes demonstrate the result as well as the 
cause of a chronic inflammatory reaction of the eye surface [8]. 
In 75% of patients with blepharitis meibom the glands that are reduced in number compares 
to the average, which is true in only 20% of healthy people. This can be detected through a 
meibography with an infrared video camera or through an infrared photograph [42]. 
Dysfunction of the meibomian glands with inflammation and obstruction has been suggested 
to be an important factor in the pathogenesis of chronic blepharitis. However, few objective tests 
are available to examine the meibomian glands directly. Studies by Messmer et al.[49] suggest that 
in vivo confocal microscopy allowed the examination of the tear film, the tarsal conjunctiva, the lid 
margin including the lash follicles and the meibomian glands. In patients with meibomian gland 
disease pathological changes could be visualised and documented objectively. The presence of an 
inflammatory infiltrate permitted us to differentiate between meibomitis and meibomian gland 
dysfunction. Changes of the lash follicles do not seem to play an important role in blepharitis. Thus, 
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in vivo confocal microscopy represents an objective technique in the classification and follow-up of 
patients with blepharitis. 
 
Accompanying illnesses of the chronic blepharitis  
 
It occurs with such frequency that CBC often coexists with keratoconjunctivitis sicca 
(KCS); there can be significant overlap of the symptoms and signs of KCS and CBC, and 
possibilities exist that both conditions may be contributing to the overall clinical picture, although a 
casual association is unproven There is a complex and dynamic interaction between eyelid surface 
abnormalities, the host’s immune system, and natural immunity involving the eyelids and tear film 
[10]. 
Infiltrating lid tumours should be suspected in patients with apparently asymmetrical or 
unilateral chronic blepharitis, particularly when associated with madarosis [22]. 
 
1.2.3 Treatment 
The most important point for the treating physician and the patient to understand relative to 
therapy is that we are dealing with a chronic disease for which we have no cure and that therapy 
will be directed initially at bringing the disease under control with intensive therapy and then 
establishing the minimal amount of chronic long-term therapy that will maintain control of the 
disease process [35]. 
 
Treatment of anterior chronic blepharitis  
Lid hygiene with warm compress for some minutes on the lids to the softening of crusts at 
the lash basis:  
Removing crusts and toxic products involves scrubbing the lid margins daily with a 
commercially available lid scrub, a cotton bud dipped in a 25% solution of baby shampoo or a week 
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solution of sodium bicarbonate. It is also useful to scrub the eyelids with diluted shampoo when 
washing the hair. Gradually, lid hygiene can be performed less frequently as the condition is 
brought under control but must not be stopped or blepharitis will recur [35]. 
Antibiotic ointment such as sodium fusidate (Fucidin), bacitracin or chloramphenicol is used 
to treat acute folliculitis but is of limited value in long-standing cases. Following lid hygiene, the 
ointment should be rubbed onto the anterior lid margin with a cotton bud or clean finger [35]. 
Oral azithromycin 500 mg daily for 3 days may be helpful to control ulcerative lid margin 
disease. 
Weak topical steroids such as fluorometholone 0, 1% q.i.d. for one week are useful in 
patients with severe papillary conjunctivitis, marginal keratitis and phlyktänulose, although repeated 
courses may be required. Tear substitutes are required for associated tear film instability and dry eye 
[35]. 
 
Treatment of posterior chronic blepharitis 
Lid hygiene with warm compress and lid massage to melt solidified sebum and mechanical 
expression of the meibomian glands are used to reduce the amount of irritating lipids within the 
glands [68]. 
Systemic tetracyclines are the mainstay of treatment but should not be used in children under 
the age of 12 years or in pregnant or breast-feeding women because they are deposited into growing 
bone and teeth and may cause staining of teeth and dental hypoplasia. One of the following 
preparations may be used: oxytetracyclin 250mg b.d for 6-12 week, doxycyclin 100mg b.d for 1 
week and then daily for 6-12 weeks, minocyclin 100 mg daily for 6-12 weeks, erythromycin 250 
mg daily or b.d. Local measures like antibiotics, steroids and tear substitutes for dry eye [35]. 
Treatment for CBC includes warm compresses, eyelid hygiene, topical antibiotics to reduce 
bacterial load, oral tetracycline analogues, and sometimes topical corticosteroids [33,62,68].  
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Local Antibiotics 
Antibiotics should only be applied with staphylococcal, mixed staphylococcal-seborrheic 
and seborrheic blepharitis as well as in case of disturbance of the Meibomian glands due to 
Rosacea. Treatment should be guided by identification of the pathogenic organism and the 
corresponding antibiogram. The most popular antibiotics in these cases are aminoglycosides or 
quinolones. Due to its modulating effect on Meibomian glands in combination with its antibiotic 
activity, oral tetracycline is one the main pillars of the treatment of the chronic blepharitis caused by 
rosacea. Locally applied metronidazol also is effective with rosacea-associated blepharitis [5]. 
Duration of antibiotic treatment (application 2-3 times daily after lid-edge hygiene) should not 
exceed more than 14 days if possible. Locally applied Salicylic acid can have some additional effect 
by inhibiting the Prostaglandin synthesis and its lightly antibiotic effect [34]. 
Studies by Ta et al. suggest that minocycline effectively decreased eyelid bacterial flora in 
patients with acne rosacea or blepharitis. One of the mechanisms of newer generation tetracycline 
analogues may be a decrease or elimination of bacterial flora from the eyelids [68]. 
Others studies recommend that a 1-day treatment with topical 0.5% levofloxacin is as 
effective as a 3-day application in healthy patients without CBC [69]. 
 
Local cortisone therapy 
Especially corneal s and episodes of heavy inflammation make cortisone application 
absolutely necessary. However, the patient must be informed about possible side-effects and the 
necessity of keeping this therapy for a short time only. Aim of all therapies, must be to avoid the 
steroid phase or to keep it rare and short. Especially peripheral corneal infiltrates in the initial stage 
can easily be intercepted with non-steroidal anti-inflammatory drugs and fusidic acid [27]. 
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Topical immune modulators 
Substances like Tacrolimus and Picrolimus can positively influence the course of anterior 
blepharitis, however, one still has to work on a formulation of the preparations for ophthalmologic 
purposes. The patients must be informed that these substances can produce a feeling of heat and 
burning, but will not affect the efficacy of the treatment. Also, this therapy should also be applied 
for a short time only [27]. 
 
1.3. Fluoroquinolones 
Fluoroquinolones are arguably the best class of antibiotics eye care specialists have ever had 
to treat and prevent ocular infections. These agents have a broad spectrum of activity; they are 
bactericidal antibiotics that kill germs rapidly and have a more than 10 years history of being 
nontoxic when used topically. In addition, this class of antimicrobials showed best ocular 
penetration of any of the commercially available topical antibiotics [41]. 
Fluoroquinolones are synthetic fluorinated analogues of nalidixic acid. Nalidixic acid, the 
first antibacterial quinolone, was introduced in 1963 during chloroquine synthesis. It is not 
fluorinated and is therefore excreted too rapidly to have systemic antibacterial effects. Quinolones 
are rapidly bactericidal and are active against a variety of gram-negative and gram-positive bacteria 
[26]. 
With a combination of convenience and efficacy, quinolones are a very attractive 
bactericidal class of drugs. The antibacterial potency of quinolones is determined primarily by their 
activity against DNA gyrase (topoisomerase II) and topoisomerase IV, two bacterial enzymes with 
distinct and essential roles in DNA synthesis, and secondarily by their ability to permeate cell 
membranes and avoid efflux to reach these intracellular targets [26]. Potency also affects the 
likelihood of development of resistance, since the frequency of selection of mutants at clinically 
relevant concentrations may be substantially lower for quinolones with a higher therapeutic index. 
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Frequency of resistance may also be reduced in quinolones with similarly high levels of activity 
against both DNA gyrase and topoisomerase IV and in those that are poor substrates for bacterial 
multidrug resistance efflux pumps [63,66].  
Infrequent ocular adverse effects associated with quinolones are discomfort, chemosis, 
hyperemia, eyelid edema, and punctuate epithelial keratitis [26]. 
Nevertheless, fluroquinolone resistance is a growing problem in ophthalmology and may 
portend a trend toward declining efficacy of older fluroquinolones (ciprofloxacin and ofloxacin). 
Newer fluroquinolones such as levoflocaxin, gatifloxacin and moxifloxacin might help to address 
this problem in two ways. First, their enhanced activity against Gram positive pathogens increases 
the probability that strains resistant to an older fluroquinolone will be susceptible to one of the 
newer fluroquinolones. Second, they are less prone to encouraging the development of resistance on 
a number of fronts, primarily because of their higher activity against Gram positive bacteria, but 
also for other reasons (higher penetration in case of levofloxacin; resistance to single-step 
topoisomerase mutations in case of gatifloxacin and moxifloxacin). Primary use of newer 
fluroquinolones in preference to initial use of older fluoroquinolones is a potential strategy for 
helping to forestall the development of resistance, but this approach must be coupled with the 
overall strategy of avoiding indiscriminate use and enduring proper dosing of these antimicrobials 
[31]. 
1.3.1 Levofloxacin 
 
Third and fourth generation fluoroquinolones available for topical ophthalmic use are: 
levofloxacin 0,5% (third generation), gatifloxacin 0,3%; and moxifloxacin 0,5% (fourth 
generation).The main advantage of these compounds is their similar stronger gram positive activity 
in comparison with older fluroquinolones [13,41]. 
Additionally, other discussed and potentially beneficial features shared by some of these 
antibiotics include enhanced drug delivery into the anterior segment, improved activity against 
 23
certain strains of atypical mycobacterium, and lowered likelihood of selection for resistant bacterial 
strains [25].  
Levofloxacin, a synthetic fluorinated carboxyquinolone, is the S (-) isomer of ofloxacin. It 
has been demonstrated that the principal antimicrobial activity of ofloxacin resides in the S (-) 
isomer. Levofloxacin is similar to the other fluoroquinolones in physicochemical, pharmacological 
and toxicological properties, but it demonstrates better antimicrobial activity than ofloxacin and is 
more soluble in water at neutral pH than the other quinolones in vitro [63]. 
Moxifloxacin and gatifloxacin have an improved spectrum of activity, increased penetration 
into ocular tissues and delayed propensity to the development of bacterial antibiotic resistance 
[31,41]. Nevertheless, levofloxacin has higher activity against gram positive pathogens and has 
shown high intraocular penetration after topical application [75]. 
 
1.4. Purpose of the study 
 
The purpose of the current study is to determine the number of days required (following a 1-
day, 3-day, and 7-day application) for topical 0.5% levofloxacin to significantly decreasing 
conjunctival bacterial flora in patients with chronic blepharoconjunctivitis (CBC).  
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2. Material and Methods 
 
2.1 Design and Ethics 
 
The study was designed as a prospective semi- randomized trial. 
It was conducted with voluntary patients to evaluate the efficacy of topical levofloxacin-
therapy on bacterial flora in patients with chronic blepharoconjunctvitis. This third generation 
fluoroquinolone with a broad spectrum and low collateral effects is frequently used for lid and 
conjunctival infections and also after intraocular surgeries [39,63]. The study was conducted 
according to the World Medical Association Declaration of Helsinki, under the Policy of “Ethical 
Principles for Medical Research Involving Human Subjects”, adopted by the 18th WMA General 
Assembly, Helsinki, Finland June 1964 [55]. 
All patients gave written informed consent for participation in this study. Patients that 
agreed to participate in the study received an information-leaflet stating details on antibiotic 
treatment and conjunctival smears.  
An application was submitted to the European Clinical Trials Database (EudraCT) and to the 
Ethics Commission of the Institutional Review Board at Ludwig-Maximilians-University for study 
approval (in German: Ethikkommision der Medizinischen Fakultät der Ludwig Maximilians 
Universität München). The research was approved by the Ethics commissions on March 2007, as 
Project Nr.4032983, with the title: “Reduction of Conjunctival/Lid Bacterial Count after 
Topical Application of 0.5% Levofloxacin in Chronic Blepharoconjunctivitis’s Patients”. The 
act was signed by Prof. Dr. G. Paumgarther, Chairman of the Ethics Commission. The insurance of 
the patients was represented by the ECCLESIA mildenberger HOSPITAL GmbH, Detmold, 
Germany, and it was supported by Santen GmbH, Germering, Germany and Georg-Hannolore 
Zimmermann Foundation, Munich, Germany. 
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2.2 Patient characteristics  
 
Participants were recruited between March 2007 and March 2008 from outpatients attending 
follow-up visits or first-time appointments at the out-patient center of the Department of 
Ophthalmology at the University of Munich (Augenklinik der Ludwig-Maximilians-Universität-
München).  
 
Inclusion criteria:  
Out-patients: 
• age 39 years or older 
• no surgery patients  
• without infectious ocular disease (Control Group) 
• with chronic blepharoconjunctivitis for more than 6 weeks 
Definition of Chronic Blepharoconjunctivitis 
o presentation of diffuse conjunctival hyperaemia 
o papillae or follicles 
o minimal mucopurulent discharge 
o conjunctival thickening persistent for more than three weeks 
 
Severity Code: 
o Mild: diffuse conjunctival hyperaemia with either papillae or follicles, minimal 
discharge, conjunctival thickening, redness and teleangiectasis of the eyelid 
o Moderate: plus lash loss, recurrent hordeola 
o Severe: plus ulceration at the base of cilia, development of cicatrises 
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Exclusion criteria: 
Out-patients: 
• under age 39 years 
• reporting to be allergic to levofloxacin 
• using topical antibiotics within the last 5 days or systemic antibiotic within the last 30 days 
• blepharoconjunctivitis only in one eye 
• with acute bleplaroconjunctivitis, dacryocystitis or history of ocular infection within 7 days. 
 
2.3 Method of randomization  
 
At the beginning of the study, a list with 100 numbers was elaborated. The Microsoft-
Office-Excel software program (Microsoft, Inc. Seattle, USA) was used to generate random 
numbers that were assigned to each group. The patients were randomized to either a control or 
study group. This randomization was distributed in sealed envelopes. Patients learned about their 
group assignment from their treating ophthalmologist, who opened the envelope and explained the 
specific treatment according to the group. 
In order to compare similarity between the groups, demographic data such as age, gender, 
eye (right or left), eye anamnesis, general anamnesis; examination and follow up were registered.  
 
2.4 Distribution of Groups  
 
In this prospective semi-randomized control trial, 60 patients diagnosed with bilateral CBC 
were enrolled in the study following Institutional Review Board approval. These patients were 
randomized to three different treatment regimens: a “no treatment” group received no antibiotic (n 
= 20); a “levofloxacin only group” treated with 0.5% topical levofloxacin in both eyes 4 times a day 
for 7 days (n = 20); a “combined group” instructed to scrub their eyelid margins with a moistened 
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cotton tip in addition to the application of 0.5% topical levofloxacin in both eyes 4 times a day for 7 
days (n = 20). The negative control group consisted of volunteers (n = 40) without CBC. (Table 1) 
 
Table 1 Distribution of Groups  
Negative control group Patients without infectious disease of the eye 
No treatment group(Positive 
Control) 
Patients with CBC will randomly receive no treatment 
for seven days. 
Levofloxacin only group 
Patients with CBC will randomly receive topical 0.5% 
levofloxacin on both eyes four times per day for seven 
days. 
Combined group 
Patients with CBC will randomly receive topical 0.5% 
levofloxacin on both eyes four times per day for seven 
days. Additionally patients will be instructed to scrub 
their eyelid margins with a moistened cotton tip 
 
2.5 Microbiological Evaluation 
 
 
Bacterial cultures were obtained from the inferior conjunctiva of both eyes using a Culture 
Swab EZ (BD-BBL™ Collection and Transport System, Becton,Dickinson and Company, USA) 
moistened with sterile thioglycolate broth (bioMerieux®), while avoiding contact with the 
eyelashes. Cultures were obtained from both eyes at baseline (D0) for all patients. Additional 
cultures were obtained from both eyes of CBC patients in the no treatment, levofloxacin and 
combined groups on day one (D1), day three (D3) and day seven (D7) after starting treatment. 
(Table 2) 
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Table 2 Description of the time points when Conjunctival Cultures were obtained. 
Time Definitions     
D0 
First smear before antibiotics 
(Baseline) 
D1 
Smears one day after the therapy 
beginning 
D3 
Smears three days after therapy 
beginning  
D7 
Smears seven days after therapy 
beginning  
 
Collection of specimens from the conjunctival sac was performed by rotation of a 
thioglycolate moistened swab through the inferior fornix from the nasal to the temporal side, 
covering all sides of the swab. Special care was taken 
• not to touch the eyelid margins or lashes.  
• not to depress the fornix as this causes slight pain an excessive sample  
• not to touch the cornea as this causes slight pain in addition to the minimum risk of corneal 
excoriation.  
The specimens were immediately inoculated first onto blood agar (BAG) for 
microaerophilic and aerobic bacteria using one side of the swab, then onto chocolate agar 
(CHOCO) plates for anaerobic bacteria (anaerobic GENbag, bioMerieux®) using the opposite side; 
by this technique, bacteria collected should have been distributed equally on both solid culture 
media and finally the swab was placed in thioglycolate broth. Thioglyolate broth, being an 
enrichment culture media, was used for detection of even small amounts of common aerobic-
microaerophilic and anaerobic bacteria. All culture media were incubated for 7 days at 37ºC. 
Bacteria were isolated and quantified. Numbers of colony-forming-units (CFUs) of aerobic and 
microaerophilic bacteria were counted on solid culture media on BAG after three days and of 
anaerobic bacteria on CHOCO after five days, respectively. This was performed using a magnifying 
glass and by counting all separately CFUs of bacteria on solid culture media. The thioglycolate 
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culture was considered to be of “positive growth” if the broth became cloudy within 7 days of 
incubation and “sterile” if after 7 days the medium maintained its clear and citrine transparent color.  
The decision of when to take a culture out of the incubator was dependent on the growth of 
bacteria. Bacterial growth was graded according to the volume of the liquid medium that was 
occupied by visible bacterial growth. Colony growth patterns were graded from one cross (+), 
indicating barely visible small colonies, to three crosses (+++), where at least 2/3 of the medium 
was occupied by bacterial growth. When positive growth of (++) or more was observed, positivity 
of growth was registered and bacteria were indentified. If after the 7 days, a positivity of one + was 
found, the culture was considered positive and the bacteria were identified. The identification of 
organisms and antibiogram were performed with the Vitek 2 Compact system (bioMérieux®). Only 
for streptococci, the isolated bacteria were tested for antibiotics susceptibilities via the Kirby-Bauer 
disk-diffusion technique for the reason that the Vitek 2 Compact system is not equipped for this 
task.  At D0 to D7, cultures were obtained without topical anesthetic to optimize bacterial growth 
by eliminating any preservative that may affect bacterial growth. The researchers collecting the 
samples and culturing the microorganisms were masked as to the treatment groups of the patients.  
 
2.6 Statistics 
 
Statistical analysis was performed using the Analyse-It software program (Analyse-It 
Software, Leeds, England). Primary variable to assess the treatment efficacy was culture positive 
rate of thioglycolate broth after seven days. For each CBC study group, a sample size of 20 patients 
(40 eyes) was planned. This was based on the assumption of a culture positive rate from 
conjunctival swabs in thioglycolate broth of 80% in the no treatment CBC group as compared to 
40% in the treatment groups. At an alpha-value of 0.05 this would give the study a power of 95%. A 
Chi-squared test was used to compare the number of positive thioglycolate broth cultures for each 
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group of patients while a Mann-Whitney test was used to compare the colony forming units (CFU) 
of bacteria isolated on blood and chocolate agars. 
Used Materials 
 
Company Culture media Reagents 
Laboratory 
materials Equiment/Instruments
bioMerieux® 
Nürtingen 
 Germany 
Blood agar 
(BAG) Gram Stain Kits anaerobic GENbag Vitek 2 Compact system 
  
Chocolate agar  
(CHOCO) 
Saline solutions 
0,45 %  Ecouvillons Swabs GP Karte  
  
McConkey 
(MKC) 
Saline solutions 
0,9 %   AST-P554 Karte  
  
Chromogenic 
culture (CPS)    GN Karte 
  
Thioglyolate 
broth    AST-N021 Karte 
      Densicheck Kalibrator 
      Densicheck 
      Dispensette 
        Pipettenspitzen 
Becton,Dickinson 
and Company, 
 (BD) USA 
Müller Hinton 
agar    
Culture Swab EZ 
   
     
Sensi Disc Antibiotic 
Susceptibility Test:  
 penicillin, oxacillin 
cefuroxim, ceftazidim 
cefotaxim, imepenem, 
meropenem,ciprofloxacin 
levofloxacin,ofloxacin, 
ciprofloxacin,norfloxacin,
moxifloxacin,gatifloxacin
neomycin,amicacin 
tobramicin,gentamicin 
erytromicinazitromycin,  
 vancomycin,tetracyclin   
      chloramphenicol,mezlocillin   
Bio Rad France Stock Culture       
Nunc. Part of 
Thermo Fisher 
Scientific. 
Denmark     
Disposable inoculating  
loops and needles    
Memmert GmbH 
Schwabach 
Germany       Incubator 
ZEISS 
Microscopy & 
Imaging  
Carl Zeiss 
MicroImaging 
GmbH, 
 Germany.       Microscopy 
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3. Results 
 
3.1 Patient characteristics 
 
Patients were enrolled in the study from March 2007 through March 2008 at the 
Ophthalmology Department of the Ludwig-Maximilians University in Munich, Germany.  
Amongst the 60 enrolled CBC patients, 52 completed the study. Conjunctival cultures were 
not obtained in 4 patients (2 in the no treatment group und 2 in the combined treated group) and 4 
patients had at least one protocol violation (2 patients each in the Levofloxacin only treated group 
and 2 in the combined group). As a result, there were 20 patients in the “no treatment group,” 17 in 
the “levofloxacin only group” and 15 in the “combined group.” 
Among the 52 remaining patients with CBC, the mean age was 62.2 years (67,3% female 
patients) (Table 3). The negative control group had a slightly lower mean age of 60 years (53% 
female patients). The most commonly type of CBC was moderate (Figure 1) (44, 2 %), following 
with mild (42, 3%) and severe (13, 5 %).   
 
Table 3 Demographic data 
 
 Age in years       Gender        Type of CBC     
 Mean F % M % Mild % Moderate % Severe % 
Control Group  n=40 60 21 53 19 48 N/A N/A N/A N/A N/A N/A
Study Group n= 52                        
No treatment group n=20                      
Levofloxacin only group n=17 62,2 35 67,3 17 32,7 22 42,3 23 44,2 7 13,5
Combined group n=15                       
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Figure 1. Show one patient with moderate chronic blepharoconjunctivitis (CBC). 
 Lid margins and conjunctival flora on blood and chocolate agar. 
 
 
 
 
 
R L RL
Fig. 1.1 Left eye, prior to any 
application of antibiotic the patient 
with CBC presented in the anterior 
lid margin: mandarosis, diffuse 
conjunctival hyperaemia and 
telangiectasie.
Fig. 1.1.1 Culture on blood agar plate (right 
and left eye ) with coagulase – negative 
Staphylococcus (big white colony) and 
Corynebacterium sp. (small white mate 
colony) 
Fig. 1.1.2 Culture on chocolate agar plate at 
the right eye with  propionibacterium acnes 
 (small pink colony)and at the left eye 
 with coagulase – negative Staphylococcus 
(big white colony) and Propionibacterium 
Fig. 1.2 Right eye after one day of 
treatment the patient presented a mild 
improvement of the signs. 
R L R L 
Fig. 1.2.1 Culture on blood agar plate  
at the right eye sterile and the left eye with 
coagulase – negative Staphylococcus  
(big white colony) 
 
Fig. 1.2.2 Culture on chocolate agar plate 
 at the right eye with  Propionibacterium acnes 
 (small pink colony)and  at the left eye 
 just one colony of Propionibacterium acnes  
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Fig. 1.4 Right eye, after seven day of 
treatment the patient presented a marked  
improvement of the signs 
 
R L R L 
Fig. 1.4.1 Culture on blood agar plate  
(right and left eye) sterile 
Fig. 1.4.2 Culture on chocolate agar plate 
 (right and left eye) with a few colony of  
Propionibacterium acnes 
 (small pink colony)  
 
Fig. 1.3 Right eye, after three day of 
treatment the patient presented a 
moderade improvement of the signs. 
R L R L 
Fig. 1.3.1 Culture on blood agar plate  
(right and left eye) sterile 
 
Fig. 1.3.2 Culture on chocolate agar plate 
 at the right eye with  Propionibacterium acnes 
 (small pink colony) and at the left eye 
 sterile 
 
 34
3.2 Bacteria 
 
Baseline culture results from both eyes demonstrated 105 bacteria isolated from the 52 CBC 
patients, compared to 46 bacteria isolated from 40 negative control patients. The most common 
bacteria isolated were coagulase-negative Staphylococcus, representing 70.5% (Table 4) of bacteria 
recovered from CBC patients and 82.6% in the negative control group. The other bacteria isolated, 
in decreasing order of frequency, included Propionibacterium acnes, Staphylococcus aureus, 
Streptococcus sp, Corynebacterium sp, Gram-negative rods, and Micrococcus sp. 
 
 
 
The thioglycolate broth culture results demonstrated that at baseline, 100 out of 106 eyes 
(95%) of patients with CBC had positive cultures, compared to only 46 out of 80 eyes (58%) from 
patients in the negative control group (P < 0.0001). Baseline positive culture in thioglycolate broth 
demonstrated significant differences between No CBC group [n = 46/80, (58%)] and No treatment  
group [n = 37/40, (88%), P = 0,0012];  Levo only group [n = 34/34, (100%), P > 0.0001] and 
Combined [n = 29/30, (97%), P = 0,0002]. After one day (D1) application of topical levofloxacin, 
the eyes of Levo only group showed a significantly reduced number of positive conjunctival 
cultures from 34/34 (100%) (D0) to 23/34 (68%) (D1), on day 3 (D3) 19/34 (56%) and after 7 days 
(D7) 10/34 (29%). Comparing No treatment group and Levo only group, a significant difference 
Table 4: Distribution of Microorganisms Isolated at baseline (D0). 
  No CBC No Treatment Levo only Combined 
CBC Patients 
Overall 
Bacteria Number % Number % Number % Number % Number % 
Coagulase negative 
Staphylococcus 38 82.6% 28 65.1% 28 80.0% 18 66.7% 74 70.5%
Staphylococcus aureus 1 2.2% 2 4.7% 2 5.7% 3 11.1% 7 6.7%
α- hemolytic Streptococcus 0 0.0% 4 9.3% 0 0.0% 1 3.7% 5 4.8%
Corynebacterium sp. 0 0.0% 3 7.0% 1 2.9% 1 3.7% 5 4.8%
Propionibacterium acnes 7 15.2% 4 9.3% 1 2.9% 2 7.4% 7 6.7%
Micrococcus sp. 0 0.0% 1 2.3% 0 0.0% 1 3.7% 2 1.9%
Gram-negative bacteria  0 0.0% 1 2.3% 3 8.6% 1 3.7% 5 4.8%
Total 46 100.0% 43 100.0% 35 100.0% 27 100.0% 105 100.0%
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was observed at all time-points (P = 0, 0117, P = 0, 0036, P = < .0001) (Figure 2 and Table 5). 
Antibiotic treatment resulted in a lower number of positive thioglycolate broth cultures. There were 
significantly fewer positive cultures following 3 and 7 days of antibiotics for the levofloxacin and 
combined group compared to untreated CBC eyes. The addition of eyelid scrub in the combined 
group did not seem to have any beneficial effect over the use of antibiotic alone. Although eyes 
treated with a combination of antibiotics and eyelid scrub had a higher culture positive rate (50%) 
compared to antibiotics alone (29%), this difference is not statistically significant (P = 0.1533).  
Thioglycolate Broth Results
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Figure 2: Percentage of Eyes with Positive Cultures in Thioglycolate Broth at Each Time Point of 
Culture Collection. CBC indicates patients with chronic blepharoconjunctivitis, therefore, “No CBC” were 
patients without chronic blepharoconjunctivitis. Patients with chronic blepharoconjunctivitis were 
randomized to the following groups: No treatment = no antibiotic; Levo only = topical levofloxacin 4 times a 
day; Combined = eyelid scrub in addition to topical levofloxacin 4 times per day. Culture collection time 
points were the following: Baseline, prior to application of any antibiotics; D1 – one day following antibiotic 
application for the levo only and combined group; D3 – three days following antibiotic application; D7 – 
seven days following antibiotic application. * Indicates significant difference compared to No CBC group.  
+ Indicates significant difference compared to no treatment group. 
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The blood agar cultures demonstrated a similar pattern as the thioglycolate broth cultures 
(Figure 3 and Table 5). Patients with CBC had significantly more positive blood agar cultures (83 
out of 106 eyes, 78%) than those without disease (30 out of 80 eyes, 38%) (P < 0.0001). At each of 
the time points following antibiotic administration, patients in the levofloxacin and combined 
groups had significantly fewer positive cultures (P < 0.05) than those who did not receive antibiotic 
(no treatment group).  
Blood Agar Culture Results
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Figure 3: Percentage of Eyes with Positive Cultures in Blood Agar at Each Time Point of Culture 
Collection. CBC indicates patients with chronic blepharoconjunctivitis, therefore, “No CBC” were patients 
without chronic blepharoconjunctivitis. Patients with chronic blepharoconjunctivitis were randomized to the 
following groups: No treatment = no antibiotic; Levo only = topical levofloxacin 4 times a day; Combined = 
eyelid scrub in addition to topical levofloxacin 4 times per day. Culture collection time points were the 
following: Baseline, prior to application of any antibiotics; D1 – one day following antibiotic application for 
the levo only and combined group; D3 – three days following antibiotic application; D7 – seven days 
following antibiotic application. * Indicates significant difference compared to No CBC group.  
+ Indicates significant difference compared to no treatment group. 
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Figure 4 and Table 5 summarizes the culture results on chocolate agar. As with the 
thioglycolate broth and blood agar results, patients with CBC had a significantly higher number of 
positive cultures (66 out of 106 eyes, 62%) than those without CBC (30 out of 80 eyes, 38%) (P = 
0.0086). Again, similar to the thioglycolate and blood agar findings, treatment with antibiotics 
resulted in a fewer number of positive cultures compared to eyes that did not receive antibiotics. 
Chocolate Agar Results
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Figure 4: Percentage of Eyes with Positive Cultures for Anaerobic Bacteria in Chocolate Agar at Each 
Time Point of Culture Collection. CBC indicates patients with chronic blepharoconjunctivitis, therefore, 
“No CBC” were patients without chronic blepharoconjunctivitis. Patients with chronic blepharoconjunctivitis 
were randomized to the following groups: No treatment = no antibiotic; Levo only = topical levofloxacin 4 
times a day; Combined = eyelid scrub in addition to topical levofloxacin 4 times per day. Culture collection 
time points were the following: Baseline, prior to application of any antibiotics; D1 – one day following 
antibiotic application for the levo only and combined group; D3 – three days following antibiotic application; 
D7 – seven days following antibiotic application. * Indicates significant difference compared to No CBC 
group.  + Indicates significant difference compared to no treatment group. 
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Table 5 : Statistical Comparisons of Number of Patients with Positive Cultures and Quantity 
of Bacteria Isolated. 
 
Comparison Thioglycolate 
broth 
Blood 
Agar 
Positive 
Blood 
Agar CFU 
Chocolate 
Agar Positive 
Chocolate 
Agar CFU 
Baseline 
No CBC vs. No treatment 0.0012 0.0003 <0.0001 0.0086 0.0001 
No CBC vs. Levo only <0.0001 0.0001 <0.0001 0.1081 0.0289 
No CBC vs. Combined 0.0002 <0.0001 <0.0001 0.1997 0.0498 
No treatment vs. Levo only 0.1060 0.7643 0.4207 0.6106 0.1322 
No treatment vs. Combined 0.3871 0.5023 0.5198 0.4899 0.3816 
Levo only vs. Combined 0.9497 0.9361 0.7302 0.9624 0.8931 
D1 
No treatment vs. Levo only 0.0117 0.0009 <0.0001 0.0043 0.0005 
No treatment vs. Combined 0.6379 0.0117 0.0019 0.0053 0.0122 
Levo only vs. Combined 0.1344 0.6484 0.1008 0.8262 0.7756 
D3 
No treatment  vs. Levo only 0.0036 <0.0001 <0.0001 0.0600 0.0091 
No treatment vs. Combined 0.0129 <0.0001 <0.0001 0.0007 0.0007 
Levo only  vs. Combined 0.9368 0.9722 0.9389 0.1850 0.2225 
D7 
No treatment  vs. Levo only <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
No treatment vs. Combined <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 
Levo only  vs. Combined 0.1533 0.2805 0.1327 0.8003 0.6876 
Values in bold are significant at a threshold of P = 0.05. Comparison of number of positive cultures was done by a χ2 
test while comparison of CFU’s was made with a Mann-Whitney test. 
 
 
In addition to analysing the blood and chocolate agar plates for positive cultures, the median 
number of colony forming units (CFU’s) was determined (Table 6). There were significantly more 
CFU’s on both blood and chocolate agar in CBC patients compared to those without CBC at 
baseline (P < 0.05). In comparing the CFU at baseline among the untreated and the treated groups, 
there were no statistically significant differences (P = 0.5023 - 0.9361). Following treatment, 
patients in groups receiving antibiotic drops consistently had fewer CFU’s isolated at each time 
point of culture collection (P < 0.05) compared to eyes without antibiotic treatment, with or without 
eyelid scrub.  
No adverse reactions attributable to the study medication occurred 
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Table 6: Median Colony Forming Units (CFU) Cultured on Blood and Chocolate Agars 
 Blood Agar Chocolate Agar 
 Baseline D1 D3 D7 Baseline D1 D3 D7 
No CBC 0 N/A N/A N/A 0 N/A N/A N/A 
No treatment 6.5* 7 8 5.5 2.5* 3.5 3 4.5 
Levo only 3* 0+ 0+ 0+ 1* 0+ 1+ 0+ 
Combined 8* 1+ 0+ 0+ 1* 0+ 0+ 0+ 
 
 
CBC indicates patients with chronic blepharoconjunctivitis, therefore, “No CBC” are patients 
without chronic blepharoconjunctivitis. Patients with chronic blepharoconjunctivitis were randomized to the 
following groups: No treatment = no antibiotic; Levo only = topical 0.5% levofloxacin 4 times a day; 
Combined = eyelid scrub in addition to topical levofloxacin 4 times per day. Culture collection time points 
were the following: Baseline – prior to application of any antibiotics; D1 – one day following antibiotic 
application for the levo only and combined group; D3 – three days following antibiotic application; D7 – 
seven days following antibiotic application. *Indicates significant difference compared to patients without 
CBC (negative control group), + indicates significant difference compared to no treatment group (patients 
with CBC who did not receive antibiotic treatment). 
 
 
Figures 5 and 5.1 show the results of antibiotic susceptibility testing (using one eye from 
each patient at Baseline) for the most common bacteria isolated in this study (coagulase-negative 
Staphylococcus). Comparing the results for “No CBC-group” and “CBC group”, there was a statistically 
significant difference for Mezlocillin (P< 0.002) and Erythromycin (P< 0.05), only.  
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Figure  5. 
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Figure 5.1 
0%
20%
40%
60%
80%
100%
Pe
rc
en
t o
f S
us
ce
pt
ib
ili
ty
MZ OX P CZ CT
X
CA
Z
CM
X
IPMME
M N AN GM NN CI
P
NO
R
OF
X
LV
X
MX
F
GA
T
AZ
M E VA TE C
Antibiotics
Coagulase negative Staphylococcus  Isolates of CBC Group  (n =45)
Resistant
Intermediate
Sensitive
 
 
 
 41
 
4. Discussion 
 
 
Chronic blepharoconjuctivitis (CBC) is one of the most common conditions seen in the 
ophthalmologist’s office; but, it is difficult to treat effectively. The disease is an extremely complex 
condition that manifests in several different and overlapping arrays of signs and symptoms [48]. 
Despite the high prevalence of this condition, blepharitis has been a poorly understood 
clinical entity, and has posed a considerable diagnostic and therapeutic challenge to practicing eye 
care providers. It has been well established that microorganisms play a significant role in the 
pathogenesis of blepharitis. An understanding of the importance of ocular microflora, meibomian 
secretions as well as their composition, and the tear film in the development of blepharitis has been 
crucial for discovering more effective regimens for treating this disease [48].  
The Fluoroquinolones have become widely used antibacterial agents in the treatment of 
ocular infections. They have good activity against Gram-negative and Gram-Positive bacteria, in 
addition to an unsurpassed ocular penetration [38,63]. Newer generation fluoroquinolones provide 
excellent efficacy against coagulase-negative staphylococci and Streptococcus group D despite a 
high number of multiresitant bacteria [37]. 
Our results demonstrated that topical 0.5% levofloxacin is effective in reducing conjunctival 
bacterial flora in patients with chronic blepharoconjunctivitis. There was a significant decrease in 
the number of bacteria present on the conjunctiva following a one-day application of topical 
levofloxacin [1,2]. The proportion of eyes with positive thioglycolate cultures was significantly 
decreased following a three-day application of topical antibiotic compared to untreated eyes, with 
further reduction after seven days of continued antibiotic use. Our results are similar to previous 
reports of bacteria eradication with ciprofloxacin in the treatment of blepharitis [9,21,50]. 
Prior to antibiotic treatment, patients with blepharitis were more likely to harbor bacteria on 
their conjunctiva compared to patients without blepharitis. The most common bacteria isolated in 
our study were coagulase-negative Staphylococcus for both patient groups, with or without chronic 
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blepharoconjunctivitis. However, normal control patients were more likely to have coagulase-
negative Staphylococcus as part of their normal bacterial flora whereas patients with blepharitis 
were more likely to have other bacteria such as Propionibacterium acnes, Staphylococcus aureus, 
and Streptococcus sp [4,24]. These findings are also consistent with published research by 
McCulley and Dougherty in addition to others [16,44].  
Coagulase negative Staphylococcus in patients with CBC showed a higher rate of resistance 
against certain antibiotics in comparison to patients without CBC. One reason might be the 
selection of resistant bacteria by previous antibiotic treatment in the CBC group. 
Our study did not demonstrate any additional beneficial effect of eyelid scrub in 
combination with topical antibiotics regarding bacterial eradication compared to topical antibiotics 
alone. In contrast, eyelid hygiene is frequently recommended for the treatment of blepharitis, 
although there are few studies demonstrating its beneficial effects [20,65,72]. 
The most likely explanation for the lack of efficacy of eyelid scrub in reducing bacterial 
count is the fact that we did not instruct the patients to use any antibacterial soap, as opposed to a 
study by Avisar et al. [6] which demonstrated the efficacy of a detergent. 
Additionally, eyelid scrub may have even caused further release of bacteria from the lid margin skin 
and glands [47,65]. Nonetheless this procedure may continue to play an important role in the 
treatment of blepharitis by mechanisms other than reducing bacterial flora, such as relieving the 
inspissated meibomian glands [46,59]. 
There are several important caveats regarding our study. First, the number of patients in 
each study group was not equal due to study incompletion for 8 patients. Despite the fewer number 
of patients completing the study than anticipated, significant differences were found between the 
antibiotic-treated and the non-treatment group at the final time-point measured at day 7. Second, 
cultures were obtained from both eyes. Therefore, the number of bacteria and response to treatment 
may be exaggerated when comparing patients with and without CBC, as well as the treatment 
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versus no treatment group. Finally, the clinical response for the treatment of CBC was not assessed 
in this study. 
Despite the above mentioned drawbacks, there are important clinical implications of our 
study. Topical levofloxacin is effective in reducing bacterial flora in patients with chronic 
blepharoconjunctivitis. Given that the cause of blepharitis is multifactorial, including inflammation 
of the eyelids due to bacterial lipases, eliminating or reducing bacterial flora may contribute to the 
treatment of blepharitis [17]. 
Furthermore, patients with blepharoconjunctivitis who are scheduled for intraocular surgery 
may benefit from a course of topical antibiotic prior to surgery to reduce the bacterial count. It has 
been reported that patients with blepharitis have a higher risk of developing postoperative 
endophthalmitis [51,58]. 
 
In summary, patients with chronic blepharoconjunctivitis are more likely to harbor bacteria 
on their conjunctiva. Topical levofloxacin 0.5% is effective in eradicating these bacteria in patients 
with blepharoconjunctivitis. Eyelid scrub did not provide additional benefit in bacterial eradication 
in patients already treated with topical antibiotics. Further studies are necessary to clarify the role of 
bacteria in the pathophysiology of blepharitis in order to develop an effective treatment for this 
chronic condition. 
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5. Summary 
 
The conjunctival flora in patients with CBC has been reported to be comprised of a greater 
number of bacteria compared to normal individuals.  
Patients with CBC who undergo intraocular surgery may be at higher risk for developing 
postoperative endophthalmitis due to an increased eyelid and conjunctiva bacterial load. Treatment 
of CBC with antibiotics to reduce bacterial load may be particularly important prior to surgery. 
The most common bacteria isolated for all groups at baseline were coagulase-negative 
Staphylococcus. Seven patients did not complete the study. Conjunctival cultures were not obtained 
in 4 patients (2 in the no treatment group und 2 in the combined group) and 4 patients had at least 
one protocol violation (2 in the Levofloxacin treated group and 2 in the combined group). The 
remaining 52 patients with CBC had a significantly higher rate of positive thioglycolate broth 
cultures (94%) compared to a 58% positive culture rate in patient without CBC (P < 0.0001). 
Treatment with at least 3 days of topical antibiotic in patient with CBC resulted in a significant 
reduction (P < 0.05) in the number of thioglycolate positive cultures (≤ 60%) compared to non-
treated eyes (≥ 88%). Following a minimum of a 1 day application of antibiotic, the median colony-
forming unit was 0-1 compared to 3-8 for eyes without antibiotic treatment (P < 0.05). Scrubbing of 
the eyelids did not provide further benefit compared to antibiotic treatment alone. 
CBC eyes have a significantly higher number of positive cultures compared to eyes without 
CBC. The application of topical 0.5% levofloxacin for at least 3 days provided significant reduction 
in the number of positive cultures as well as the number of bacteria harbored on the conjunctival 
surface. 
 
In summary, patients with chronic blepharoconjunctivitis are more likely to harbor bacteria 
on their conjunctiva. Topical levofloxacin 0.5% is effective in eradicating these bacteria in patients 
with blepharoconjunctivitis. Eyelid scrub did not provide additional benefit in bacterial eradication 
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in patients already treated with topical antibiotics. Further studies are necessary to clarify the role of 
bacteria in the pathophysiology of blepharitis in order to develop an effective treatment for this 
chronic condition. 
 
Zusammenfassung 
 
In Studien konnte bereits gezeigt werden, dass die konjunktivale Flora bei Patienten mit 
chronischer Blepharokonjunktivitis (CBC) im Vergleich zu einer gesunden Kontrollgruppe eine 
größere Anzahl an Bakterien aufweist. Patienten mit CBC, die sich intraokularen Operationen 
unterziehen, haben ein höheres Risiko eine postoperative Endophthalmitis zu entwickeln, was auf 
eine höhere Anzahl an Bakterien (Keimlast) an Augenlidern und Konjunktiva zurückzuführen ist. 
Eine präoperative Behandlung der CBC zur Reduktion der Keimzahl könnte daher einen 
bedeutenden Faktor zur Reduktion postoperativer Infektionen darstellen. 
Der häufigste Keim, der bei allen Gruppen vor Therapiebeginn isoliert werden konnte, 
waren Koagulase negative Staphylokokken. Insgesamt wurden 60 Patienten in die Studie 
eingeschlossen. Am Ende wurden sieben Patienten aus folgenden Gründen in der Auswertung 
ausgeschlossen: Verpasste Bindenhautabstriche zu irgendeinem Zeitpunkt bei 4 Patienten (2 in der 
unbehandelten Gruppe und 2 in der kombiniert behandelten Gruppe) und wenigstens eine 
Protokollverletzung bei 4 Patienten (2 in der allein mit Levofloxacin behandelten Gruppe und 2 in 
der kombiniert behandelten Gruppe). Die restlichen 52 Patienten mit CBC hatten eine signifikant 
höhere Rate an positiven Thioglycolat Bouillon Kulturen (94%) verglichen mit Patienten ohne CBC 
(58%, P < 0.0001). Eine mindestens 3-tägige Behandlung von Patienten mit CBC mit einem 
topischen Antibiotikum führte zu einer signifikanten Reduktion (P < 0.05) der Anzahl an 
Thioglykolat positiven Kulturen (≤ 60%) im Vergleich zu nicht behandelten Augen (≥ 88%). 
Nach mindestens 1-tägiger Applikation des topischen Antibiotikums, lag die mittlere 
koloniebildende Einheit (KBE) bei 0-1 verglichen mit 3-8 bei nicht behandelten Augen (P < 0.05). 
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Eine additive Lidkantenpflege brachte keinen zusätzlichen Vorteil verglichen mit der topischen 
Antibiotikabehandlung alleine. 
Augen mit CBC wiesen im Vergleich zu gesunden Augen eine signifikant höhere Anzahl 
positiver Kulturen auf. Die Anwendung von 0.5% Levofloxacin für mindestens 3 Tage führte zu 
einer signifikanten Reduktion der Anzahl an positiven Kulturen und der Keimzahl auf der 
konjunktivalen Oberfläche. 
 
Zusammenfassend lässt sich festhalten, dass Patienten mit Blepharokonjunktivitis mehr 
Bakterien auf der konjunktivalen Oberfläche aufweisen. Die topische Anwendung von 
Levofloxacin 0.5% bei Patienten mit chronischer Blepharokonjunktivitis führte zu einer effizienten 
Eradikation dieser Bakterien. Lidkantenpflege zusätzlich zur topischen Antibiotikatherapie 
erbrachte keinen additiven Effekt. Weitere Studien sind notwendig, um die Rolle von Bakterien in 
der Pathophysiologie der Blepharitis zu klären und eine effiziente Behandlung dieser chronischen 
Augenerkrankung entwickeln zu können. 
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